Report
Moderna’s personalized mRNA cancer vaccine reportedly gets positive phase 3 results; efficacy figures expected October 24
A Substack writer says the announcement gave no efficacy numbers, while Moderna’s stock rose 177 percent.
TLDR
A Substack writer says Moderna’s personalized mRNA cancer vaccine had a positive phase 3 result, but the announcement disclosed no efficacy numbers. The writer says Moderna’s stock rose 177 percent and expects the figures at ESMO on October 24, 2026.
Combined views
1
1 Source, first seen ago